ISPE and PDA take on the challenge of recommending quality metrics.
Single-use systems and other technologies drive process efficiencies, but there is room for improvement.
Generics, market dynamics, and global demand are changing drug spending patterns.
Higher wages and employment rates give biopharm professionals an edge over counterparts in other industries.
The employment picture brightened a bit, but biopharma employees still seek better compensation.
The JOBS Act and FDASIA show early signs of accelerating drug development.
As the Supreme Court ruled on generic-drug liability, FDA outlined new rules for warning labels.
Pharma and biotech companies, with the rest of the healthcare industry, must face change.
Ranbaxy's $500 million settlement for producing adulterated drugs and fradulent data provides a cautionary tale for patients, FDA, and drug manufacturers.